Logo Logo Logo Logo Logo
  • COMPANY
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • Contact Us
  • TECHNOLOGIES
    • OPTIREACH Technology
    • Antibody Fragment Technology
  • PIPELINE
    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
    • OCS-05 Glaucoma
  • NEWS
    • Press Releases
    • Articles
  • CAREERS
  • COMPANY

    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • Contact Us
  • TECHNOLOGIES

    • OPTIREACH Technology
    • Antibody Fragment Technology
  • PIPELINE

    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
    • OCS-05 Glaucoma
  • NEWS

    • Press Releases
    • Articles
  • CAREERS

Press Releases

June 29, 2022

 

First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 for Inflammation and Pain following Cataract Surgery

March 2, 2022

 

Oculis Strengthens Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma

February 8, 2022

 

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

January 5, 2022

 

Oculis appoints Mr. Webb Ding as Global COO and GM China

November 12, 2021

 

Oculis Announces Patient Dosing in its First Phase 3 with OCS-01 for Diabetic Macular Edema (DIAMOND Study)

October 7, 2021

 

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office

May 11, 2021

 

Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, Presented at ARVO 2021

May 04, 2021

 

Oculis Announces an Oversubscribed US$57 million Series C Financing

Press Releases 2020
Press Releases 2019
Press Releases 2018
Contact us

Oculis Switzerland
Corporate Headquarters
EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne
Switzerland

+41 21 711 3970

 

info@oculis.com

Copyright © 2022 Oculis SA.

 

    © Oculis – Privacy Policy – Terms of Use  – Cookie Policy    

    © L’autreagence 2019 – 2022